{"id":5275,"date":"2025-02-23T14:09:00","date_gmt":"2025-02-23T14:09:00","guid":{"rendered":"https:\/\/www.orthogate.org\/press\/uncategorized\/txa-in-total-joint-arthroplasty\/"},"modified":"2025-02-23T22:54:55","modified_gmt":"2025-02-23T22:54:55","slug":"txa-in-total-joint-arthroplasty","status":"publish","type":"post","link":"https:\/\/www.orthogate.org\/press\/deep-research\/joint-arthroplasty-balancing-innovation-and-evidence\/txa-in-total-joint-arthroplasty\/","title":{"rendered":"TXA in Total Joint Arthroplasty"},"content":{"rendered":"

Tranexamic Acid in Total Joint Arthroplasty: A Review of Evidence for Reducing Blood Loss and Transfusion Rates<\/span><\/span><\/h1>\n

The “stop the bleed” campaign, launched in 2013, highlights the critical importance of hemorrhage control in medical emergencies<\/span> 1<\/sup><\/span>. In the context of elective surgical procedures, such as total joint arthroplasty (TJA), effective blood management is crucial for optimizing patient outcomes and minimizing complications. Tranexamic acid (TXA), an antifibrinolytic medication, has emerged as a valuable tool in this endeavor. By inhibiting the breakdown of fibrin, TXA helps to stabilize blood clots and reduce bleeding. This comprehensive review examines the evidence supporting the use of TXA in TJA, focusing on its impact on blood loss, transfusion rates, optimal dosing regimens, and potential risks.<\/span><\/p>\n

Evidence Supporting TXA Use in TJA<\/span><\/span><\/h2>\n

This review encompasses a variety of studies, including meta-analyses, randomized controlled trials (RCTs), and retrospective studies, to provide a comprehensive overview of the research landscape on TXA in TJA. These studies consistently demonstrate that TXA effectively reduces blood loss and transfusion rates in patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA).<\/span><\/p>\n

A meta-analysis of over 2 million patients found that TXA use was associated with a lower risk of periprosthetic joint infection (PJI)<\/span> 2<\/sup><\/span>. Another meta-analysis, which included 83 high-quality studies, provided significant evidence for TXA’s ability to reduce blood loss and the need for transfusion in primary THA and TKA<\/span> 3<\/sup><\/span>. A network meta-analysis further supported these findings, showing that various routes of TXA administration, including intravenous (IV), topical, and oral, effectively reduced blood loss and transfusion rates compared to placebo<\/span> 3<\/sup><\/span>.<\/span><\/p>\n

Several RCTs have also demonstrated the benefits of TXA in TJA. For example, a study comparing IV TXA with epsilon-aminocaproic acid (EACA) in 235 patients found that TXA was associated with reduced blood loss in TKA<\/span> 4<\/sup><\/span>. Another RCT, which included 1,086 patients, showed that extended oral dosing of TXA significantly reduced blood loss in TKA but not THA<\/span> 5<\/sup><\/span>. This study also highlighted the cost-effectiveness of TXA, with significant cost savings observed due to reduced length of stay, readmission rates, and blood transfusions<\/span> 5<\/sup><\/span>.<\/span><\/p>\n

To understand the clinical significance of blood loss reduction, it’s important to consider the classification of hemorrhage severity. Hemorrhage is categorized into four classes (I-IV) based on the percentage of blood volume loss, with increasing severity and associated symptoms ranging from minimal changes in vital signs to significant hemodynamic instability and potential organ damage<\/span> 6<\/sup><\/span>. By reducing blood loss, TXA can help to prevent patients from progressing to higher hemorrhage classes and minimize the associated risks.<\/span><\/p>\n

Optimal Dosing Regimens<\/span><\/span><\/h2>\n

While the evidence clearly supports the use of TXA in TJA, the optimal dosing regimen remains a topic of debate, and there is no universally agreed-upon optimal dose and regimen. Studies have investigated different doses, timings, and routes of administration, with varying results.<\/span><\/p>\n

Dosage<\/span><\/span><\/h3>\n

A meta-analysis of five studies comparing single-dose (1 g) versus two-dose (1 g each) IV TXA found a significant difference in total blood loss, with the two-dose regimen showing greater reduction, although there was no significant difference in transfusion rates<\/span> 7<\/sup><\/span>. This suggests that a single dose may be sufficient for many patients, especially those with lower preoperative hemoglobin levels<\/span> 8<\/sup><\/span>. However, a retrospective study of 1,520 patients found that a three-day prolonged course of multiple-dose TXA was more effective in reducing postoperative hemoglobin drops and estimated total blood loss compared to a single dose<\/span> 9<\/sup><\/span>.<\/span><\/p>\n

Typically, doses used in hip and knee arthroplasty range from 1 to 2 g perioperatively<\/span> 10<\/sup><\/span>. These doses are lower than those used in other surgeries, such as cardiac surgery (1- to 2-g bolus with 0.4 to 1 g\/h) and treatment of menstrual bleeding (3 to 4 g\/d for 4 to 5 days)<\/span> 10<\/sup><\/span>.<\/span><\/p>\n

Timing<\/span><\/span><\/h3>\n

A study of 240 TKA patients found that a pre-operative dose of TXA (10 mg\/kg) given 20 minutes before tourniquet inflation, plus an intraoperative dose given 15 minutes before tourniquet deflation, effectively reduced total blood loss<\/span> 11<\/sup><\/span>. In THA, a study of 107 patients showed that 1 g of TXA given 10 minutes before surgery and again 6 hours later was the most effective regimen for reducing blood loss<\/span> 11<\/sup><\/span>. Importantly, a meta-analysis indicated that pre-incision administration of TXA may be more effective in reducing blood loss and transfusion needs compared to administration at other time points<\/span> 3<\/sup><\/span>.<\/span><\/p>\n

Route of Administration<\/span><\/span><\/h3>\n

IV and topical TXA have been shown to be equally effective in reducing blood loss and transfusion rates<\/span> 3<\/sup><\/span>. However, some studies suggest that a combination of IV and topical TXA may provide better hemostasis<\/span> 12<\/sup><\/span>. Oral TXA has also been shown to be effective, but its impact on transfusion rates is less clear<\/span> 3<\/sup><\/span>.<\/span><\/p>\n

Potential Risks<\/span><\/span><\/h2>\n

Despite its benefits, TXA is not without potential risks. The primary concern is an increased risk of thromboembolic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), due to its antifibrinolytic properties. However, several studies have investigated this risk and found no evidence of an increased incidence of VTE with TXA use in TJA<\/span> 11<\/sup><\/span>.<\/span><\/p>\n

A meta-analysis of RCTs specifically evaluated the safety of TXA in THA and TKA and found no association between TXA use and an increased risk of VTE<\/span> 13<\/sup><\/span>. Furthermore, a meta-regression analysis showed that TXA use in patients with an American Society of Anesthesiologists (ASA) score of 3 or greater (indicating higher comorbidity burden) was not associated with an increased risk of VTE after TKA<\/span> 13<\/sup><\/span>. It’s important to note that the ASA score has limitations as a sole indicator of risk for thromboembolic events, and other factors should be considered in individual patient assessments<\/span> 13<\/sup><\/span>.<\/span><\/p>\n

While most studies agree that thrombosis due to TXA is unlikely, new research in cells and animal models is evaluating whether TXA can negatively impact other aspects of musculoskeletal physiology, although the results thus far have been conflicting<\/span> 14<\/sup><\/span>.<\/span><\/p>\n

Other potential risks of TXA include seizures, visual disturbances, and allergic reactions, although these are rare occurrences. (Please consult additional sources for specific data on the incidence of these adverse effects.)<\/span><\/p>\n

TXA in Revision TJA<\/span><\/span><\/h2>\n

A meta-analysis of seven studies evaluating the use of intravenous TXA in revision TJA found that TXA significantly reduced blood transfusion requirements without increasing the risk of VTE<\/span> 15<\/sup><\/span>. This suggests that TXA can be a valuable tool for blood management in more complex TJA procedures. There is also a potential role for TXA use in foot and ankle procedures, although limited studies are available to support this<\/span> 16<\/sup><\/span>.<\/span><\/p>\n

Conclusion<\/span><\/span><\/h2>\n

The evidence overwhelmingly supports the use of TXA in TJA to reduce blood loss and transfusion rates. While the optimal dosing regimen is still being refined, current research suggests that a single IV dose administered pre-operatively is effective for most patients. Topical and combined IV\/topical routes may also be considered. Although there are theoretical concerns about thromboembolic complications, studies have not shown an increased risk with TXA use in TJA.<\/span><\/p>\n

Synthesis of Findings<\/span><\/span><\/h2>\n

TXA is a valuable tool for blood management in TJA, with proven efficacy in reducing blood loss and transfusion rates<\/span> 3<\/sup><\/span>.<\/span><\/p>\n\n\n\n\n\n\n\n\n
Outcome<\/b><\/span><\/th>\nTXA Effect<\/b><\/span><\/th>\nEvidence Level<\/b><\/span><\/th>\nSupporting Evidence<\/b><\/span><\/th>\n<\/tr>\n<\/thead>\n
Blood Loss<\/span><\/td>\nReduced by an average of 300-500 mL<\/span><\/td>\nHigh<\/span><\/td>\nMeta-analyses and RCTs<\/span> 3<\/sup><\/span><\/td>\n<\/tr>\n
Transfusion Rates<\/span><\/td>\nReduced by approximately 30-45%<\/span><\/td>\nHigh<\/span><\/td>\nMeta-analyses and RCTs<\/span> 3<\/sup><\/span><\/td>\n<\/tr>\n
Periprosthetic Joint Infection<\/span><\/td>\nReduced Risk<\/span><\/td>\nModerate<\/span><\/td>\nEvidence from meta-analysis<\/span> 2<\/sup><\/span><\/td>\n<\/tr>\n
Thromboembolic Events<\/span><\/td>\nNo Increased Risk<\/span><\/td>\nModerate<\/span><\/td>\nEvidence from meta-analyses and RCTs<\/span> 11<\/sup><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Optimal Dosing:<\/b><\/span><\/p>\n

    \n
  1. Dosage:<\/b><\/span> A single IV dose (1 g) may be sufficient for many patients, but further research is needed to determine the optimal dose for different patient populations and surgical procedures.<\/span><\/li>\n
  2. Route:<\/b><\/span> IV, topical, or combined IV\/topical<\/span><\/li>\n
  3. Timing:<\/b><\/span> Pre-incision administration appears to be more beneficial in reducing blood loss and transfusion needs.<\/span><\/li>\n<\/ol>\n

    Potential Risks:<\/b><\/span><\/p>\n

      \n
    1. Thromboembolic events: While studies have not shown an increased risk, clinicians should remain vigilant, especially in patients with pre-existing risk factors.<\/span><\/li>\n
    2. Potential negative effects on musculoskeletal physiology: Ongoing research with conflicting results.<\/span><\/li>\n
    3. Rare adverse effects: Seizures, visual disturbances, and allergic reactions.<\/span><\/li>\n<\/ol>\n

      This review highlights the importance of considering TXA as part of a comprehensive blood management strategy in TJA. Future research should focus on refining optimal dosing regimens, further evaluating the long-term safety of TXA in various patient populations, and exploring its potential role in other orthopedic procedures, such as foot and ankle surgery.<\/span><\/p>\n

      Works cited<\/span><\/h4>\n

      1. Hemorrhage Control – StatPearls – NCBI Bookshelf, accessed February 17, 2025, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535393\/<\/a><\/p>\n

      2. Association Between Tranexamic Acid and Decreased … – PubMed, accessed February 17, 2025, https:\/\/pubmed.ncbi.nlm.nih.gov\/38636676\/<\/a><\/p>\n

      3. www.aaos.org, accessed February 17, 2025, https:\/\/www.aaos.org\/globalassets\/quality-and-practice-resources\/txa\/txa-clinical-guidelines.pdf<\/a><\/p>\n

      4. Tranexamic acid or epsilon-aminocaproic acid in total joint …, accessed February 17, 2025, https:\/\/pubmed.ncbi.nlm.nih.gov\/31474134\/<\/a><\/p>\n

      5. Using tranexamic acid for an additional 24 hours postoperatively in …, accessed February 17, 2025, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9350706\/<\/a><\/p>\n

      6. Hemorrhage – StatPearls – NCBI Bookshelf, accessed February 17, 2025, https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542273\/<\/a><\/p>\n

      7. Efficacy and safety of single- and double-dose intravenous tranexamic acid in hip and knee arthroplasty: a systematic review and meta-analysis – PubMed, accessed February 17, 2025, https:\/\/pubmed.ncbi.nlm.nih.gov\/37563702\/<\/a><\/p>\n

      8. One Dose Versus Two Doses of Intravenous Tranexamic Acid in Total Joint Arthroplasty, accessed February 17, 2025, https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8166358\/<\/a><\/p>\n

      9. Efficacy of a three-day prolonged-course of multiple-dose versus a single-dose of tranexamic acid in total hip and knee arthroplasty, accessed February 17, 2025, https:\/\/atm.amegroups.org\/article\/view\/37469\/html<\/a><\/p>\n

      10. Tranexamic Acid in Hip and Knee Arthroplasty, accessed February 17, 2025, https:\/\/www.wosm.com\/wp-content\/uploads\/2017\/07\/TXA-in-hip-and-knee-arthroplasty.pdf<\/a><\/p>\n

      11. pubmed.ncbi.nlm.nih.gov, accessed February 17, 2025, https:\/\/pubmed.ncbi.nlm.nih.gov\/29699826\/#:~:text=Results%3A%20Topical%2C%20intravenous%2C%20and,VTE%20after%20total%20knee%20arthroplasty.<\/a><\/p>\n

      12. Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials | BMJ Open, accessed February 17, 2025, https:\/\/bmjopen.bmj.com\/content\/9\/1\/e024350<\/a><\/p>\n

      13. The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis – PubMed, accessed February 17, 2025, https:\/\/pubmed.ncbi.nlm.nih.gov\/29699826\/<\/a><\/p>\n

      14. Utilization of Tranexamic Acid in Orthopaedic Surgery | ORR – Dove Medical Press, accessed February 17, 2025, https:\/\/www.dovepress.com\/utilization-of-tranexamic-acid-in-surgical-orthopaedic-practice-indica-peer-reviewed-fulltext-article-ORR<\/a><\/p>\n

      15. Intravenous tranexamic acid use in revision total joint arthroplasty: a meta-analysis, accessed February 17, 2025, https:\/\/www.dovepress.com\/intravenous-tranexamic-acid-use-in-revision-total-joint-arthroplasty-a-peer-reviewed-fulltext-article-DDDT<\/a><\/p>\n

      16. Tranexamic Acid in Foot and Ankle Surgery: A Topical Review and Value Analysis – Prisma Health, accessed February 17, 2025, https:\/\/prismahealth.org\/getmedia\/b2cb7e2e-cb38-4952-82f1-5b1226a4230b\/johns-et-al-2021-tranexamic-acid-in-foot-and-ankle-surgery-a-topical-review-and-value-analysis.pdf<\/a><\/p>","protected":false},"excerpt":{"rendered":"

      Tranexamic Acid in Total Joint Arthroplasty: A Review of Evidence for Reducing Blood Loss and Transfusion Rates The “stop the bleed” campaign, launched in 2013, highlights the critical importance of hemorrhage control in medical emergencies 1. In the context of elective surgical procedures, such as total joint arthroplasty (TJA), effective blood management is crucial for […]<\/p>\n","protected":false},"author":1,"featured_media":5315,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[527],"tags":[620,621,366,624,594,591,619,623,622,625],"class_list":["post-5275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-joint-arthroplasty-balancing-innovation-and-evidence","tag-blood-loss","tag-dosing","tag-hemorrhage","tag-risks","tag-tja","tag-total-joint-arthroplasty","tag-tranexamic-acid","tag-transfusion","tag-txa","tag-vte"],"_links":{"self":[{"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/posts\/5275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/comments?post=5275"}],"version-history":[{"count":0,"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/posts\/5275\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/media\/5315"}],"wp:attachment":[{"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/media?parent=5275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/categories?post=5275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.orthogate.org\/press\/wp-json\/wp\/v2\/tags?post=5275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}